Company Overview: Anavex Life Sciences Corp

Industry News

3 Mar

Anavex to Present at 27th Annual ROTH Conference on March 11th

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 27th Annual ROTH Conference on Wednesday, March 11, 2015 at 11:00 a.m. PT in Salon 2 at the Ritz Carlton in Dana Point, California....

Read more

18 Feb

Anavex Reports Fiscal First Quarter 2015 Financial Results

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months ended December 31, 2014. Financial Highlights: Anavex had cash...

Read more

9 Feb

Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73 – Validation as Potential Platform Drug for Multiple Neurodegenerative Diseases

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL) today confirmed positive preclinical data for its lead drug candidate ANAVEX 2-73 for the potential treatment of epilepsy, validating it also as a prospective platform drug for the treatment of other neurodegenerative diseases beyond Alzheimer’s. The data demonstrates significant improvement...

Read more

8 Jan

Anavex Announces Panel Discussion and Presention at OneMedForum Conference

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical stage biopharmaceutical company currently in a Phase2a clinical trial for Alzheimer’s disease, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in a panel discussion entitled “Neurology and Brain Health” and will present...

Read more

6 Jan

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction With Cannabinoid Receptor

Report Expands Opportunity for Therapeutic Application of Proprietary Anavex Compounds in Neurological Diseases- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL) welcomes new data published in the current issue of the International Journal of Neuropsychopharmacology (IJNP) revealing that the sigma-1 receptor, the Company’s drug target, interacts positively and...

Read more

30 Dec

Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today reported fourth quarter and year-end results for fiscal year 2014. Upcoming Near-Term Milestones: First...

Read more

18 Dec

Anavex to Present at Biotech Showcase 2015 in San Francisco

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, will present at Biotech Showcase 2015 on Monday January 12, 2015 at 2:00pm PST. The...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address